Clinical Trial

Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
This study suggests that R-IDARAM combined with intrathecal immunochemotherapy may be high effective in primary central nervous system lymphoma (PCNSL) patients.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2016-01-15; most recent amendment 2020-09-08.
Status change: Enrolling by Invitation → Recruiting 2019-05-23
Status change: Recruiting → Enrolling by Invitation 2016-09-25
Trial Details
NCT Number NCT02657785
Lead Sponsor Navy General Hospital, Beijing
Conditions Primary Central Nervous System Lymphoma
Enrollment 100 participants
Start Date 2010-09
Primary Completion 2028-12 (estimated)
Study Completion 2030-12 (estimated)
Updated on ClinicalTrials.gov 2020-09-09